48 studies found for:    "Camurati-Engelmann disease" [DISEASE] OR NCT00001754 [ID-NUMBER]
Show Display Options
RSS Create an RSS feed from your search for:
"Camurati-Engelmann disease" [DISEASE] OR NCT00001754 [ID-NUMBER]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Intervention: Genetic: DNR.NPC-specific CTLs
2 Completed Angiotensin II Antagonism of TGF-Beta 1
Conditions: Diabetic Nephropathy;   Hypertension
Intervention: Drug: Candesartan
3 Completed Study of Skeletal Disorders and Short Stature
Conditions: Developmental Bone Disease;   Dwarfism;   Skeletal Dysplasias
Intervention:
4 Recruiting Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy
Condition: HER2 Positive Malignancies
Intervention: Genetic: TGFBeta resistant HER2/EBV-CTLs
5 Unknown  Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus
Condition: Normal Pressure Hydrocephalus
Intervention: Other: CSF collection
6 Completed Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers
Condition: Healthy
Interventions: Drug: P144 cream;   Drug: Placebo
7 Completed Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
Conditions: Pancreatic Neoplasms;   Melanoma;   Colorectal Neoplasms
Intervention: Drug: AP 12009
8 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
9 Recruiting Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)
Conditions: Lymphoma;   Hodgkin's Disease;   Relapse;   Lymphoma, Non-Hodgkin
Intervention: Genetic: TGFbeta resistant LMP-specific CTLs
10 Recruiting TGF-(Beta) and Susceptibility to RSV
Conditions: Respiratory Syncytial Virus;   Asthma
Intervention:
11 Completed Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Interventions: Drug: AP 12009 10 µM;   Drug: AP 12009 80 µM;   Drug: temozolomide or PCV;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System
12 Completed Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma
Condition: Asthma
Intervention: Drug: montelukast
13 Completed
Has Results
Anti-TGF-beta Therapy in Patients With Myelofibrosis
Conditions: Myelofibrosis;   Primary Myelofibrosis;   Post-polycythemia Vera Related Myelofibrosis;   Post-essential Thrombocythemia Related Myelofibrosis
Intervention: Biological: monoclonal antibody to TGF-beta
14 Withdrawn Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome
Condition: Marfan Syndrome
Intervention: Other: Blood draw
15 Completed Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Lung Cancer;   Prostate Cancer
Interventions: Procedure: venipuncture;   Radiation: radiation therapy
16 Completed Fresolimumab In Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Intervention: Drug: Fresolimumab
17 Completed Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer
Conditions: Lung Neoplasm;   Carcinoma, Bronchogenic
Intervention: Biological: Lucanix
18 Not yet recruiting Tumor Infiltrating Lymphocytes (TIL) Transduced With TGFbDNRII
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires
19 Completed Radiation Therapy in Treating Women With Invasive Breast Cancer
Condition: Breast Cancer
Interventions: Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Radiation: radiation therapy
20 Completed Effect of Montelukast on Remodelling Markers in Asthmatic Children
Condition: Asthma
Interventions: Drug: Montelukast;   Drug: placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years